BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics for $4.8 billion in an all‑cash deal that adds two marketed therapies for Fabry and Pompe diseases and U.S. rights to a Phase III candidate for focal segmental glomerulosclerosis (DMX‑200). Boards of both companies approved the transaction, which is expected to close in the second quarter of 2026. BioMarin will pick up Galafold (migalastat) and the cipaglucosidase alfa/miglustat combination marketed for Pompe disease, expanding its commercial rare‑disease footprint. Management projects revenue synergies and cost savings as the acquirer integrates Amicus’ portfolio and global reach. Analysts flagged the deal as defensive and accretive: it secures immediate revenue streams while adding a late‑stage asset that could diversify BioMarin’s pipeline beyond its gene‑therapy investments.